Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 141 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Luteinizing Hormone-Releasing Hormone Analog Clear all
Completed Phase 3 Interventional

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 13, 2026, 4:49 PM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 13, 2026, 4:49 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

NCT00206375
View directory record Official record
Conditions
Hypothyroidism
Interventions
Growth hormone, Growth hormone treatment and puberty
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 13, 2026, 4:49 PM EDT
Active, not recruiting Phase 4 Interventional

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

NCT03016741
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 13, 2026, 4:49 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Drug · Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

NCT00667446
View directory record Official record
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

NCT00454571
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
pazopanib hydrochloride, leuprolide acetate, goserelin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 13, 2026, 4:49 PM EDT
Terminated Phase 4 Interventional

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 13, 2026, 4:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 13, 2026, 4:49 PM EDT
Withdrawn Phase 4 Interventional

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

NCT00507780
View directory record Official record
Conditions
Ovarian Function, Preservation of Ovarian Function
Interventions
GnRH antagonist
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 21 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

NCT00659373
View directory record Official record
Conditions
Breast Cancer, Fatigue, Sleep Disorders
Interventions
Tamoxifen, triptorelin, Exemestane
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
Up to 120 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
13
States / cities
Sacramento, California • Fort Collins, Colorado • Norwalk, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 13, 2026, 4:49 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Understanding Experimentally Induced Hot Flushes

NCT00455689
View directory record Official record
Conditions
Hot Flashes
Interventions
Leuprolide acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 13, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066703
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, tamoxifen, triptorelin
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
2,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
139
States / cities
Burbank, California • La Jolla, California • Mission Hills, California + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 13, 2026, 4:49 PM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 13, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

NCT00103376
View directory record Official record
Conditions
Prostate Cancer
Interventions
Velcade, LH-RH Agonist, Androgen Receptor Antagonists
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
4
States / cities
Loma Linda, California • Charleston, South Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 13, 2026, 4:49 PM EDT